Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 mai 2021 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer

PHILADELPHIA and BALTIMORE, May 06, 2021 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today...
09 nov. 2020 08h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics Presents New Marrow-Infiltrating Lymphocytes (MILs®) Data Demonstrating Broad Therapeutic Promise for Solid Tumor Cancers

PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer...
20 oct. 2020 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs®) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

PHILADELPHIA and BALTIMORE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer...
13 oct. 2020 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics and Stephenson Cancer Center Announce Collaboration to Collect Bone Marrow from Patients with Renal and Urothelial Carcinomas to Develop Marrow Infiltrating Lymphocytes (MILs®)

PHILADELPHIA, BALTIMORE and OKLAHOMA CITY, Oct. 13, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and Stephenson Cancer Center today announced that the first patients have been identified...
05 oct. 2020 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

PHILADELPHIA and BALTIMORE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer...
03 sept. 2020 07h30 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics to Present at Citi's 15th Annual BioPharma Virtual Conference

PHILADELPHIA and BALTIMORE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer...
28 mai 2020 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo®) for the Treatment of Non-Small Cell Lung Cancer

PHILADELPHIA and BALTIMORE, May 28, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today...
27 mai 2020 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics to Present at Jefferies Virtual Healthcare Conference 2020

PHILADELPHIA and BALTIMORE, May 27, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today...
12 mai 2020 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics to Present at UBS Virtual Global Healthcare Conference

PHILADELPHIA and BALTIMORE, May 12, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today...
21 avr. 2020 07h00 HE | Source: WindMIL Therapeutics

WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

PHILADELPHIA and BALTIMORE, April 21, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today...

Page suivante